Cart
sales@molnova.com
Pirtobrutinib
CAS No. 2101700-15-4
Pirtobrutinib( LOXO-305 )
Catalog No. M28068 CAS No. 2101700-15-4
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 72 | In Stock |
|
| 5MG | 68 | In Stock |
|
| 10MG | 122 | In Stock |
|
| 25MG | 282 | In Stock |
|
| 50MG | 425 | In Stock |
|
| 100MG | 625 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1330 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePirtobrutinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionPirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations.
-
DescriptionPirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM.(In Vitro):Pirtobrutinib potently inhibits both wild-type BTK and BTK C481S-mediated kinase activity with nanomolar potency. Pirtobrutinib inhibits WT BTK (Y223) autophosphorylation with an IC50 of 3.68 nM. Pirtobrutinib inhibits BTK C481S Y223, C481T Y223, and C481R Y223 autophosphorylation with IC50s of 8.45, 7.23, and 11.73 nM, respectively.
-
In Vitro——
-
In Vivo——
-
SynonymsLOXO-305
-
PathwayTyrosine Kinase
-
TargetBTK
-
Recptor8-oxoguanine DNA glycosylase 1 (OGG1)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2101700-15-4
-
Formula Weight479.43
-
Molecular FormulaC22H21F4N5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (104.29 mM)
-
SMILESN/A
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Baptiste BA, et al. Enhanced mitochondrial DNA repair of the common disease-associated variant, Ser326Cys, of hOGG1 through small molecule intervention. Free Radic Biol Med. 2018 Aug 20;124:149-162.
molnova catalog
related products
-
(R)-Zanubrutinib
(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).
-
Atuzabrutinib
Atuzabrutinib (SAR 444727) is a selective Bruton's tyrosine kinase (Btk) inhibitor that inhibits intra-neutrophilic neutrophilic granulocytes through inhibition of the adhesion receptor signaling pathway, and can be used to study autoimmune disorders such as arthritis in rheumatoid rodents and pemphigus vulgaris.
-
LFM-A13
A highly specific inhibitor of BTK with Ki of 1.4 uM, IC50 of 17.2 uM.
